Printed in U.S.A. Copyright © 1998 by The Endocrine Society p53 Regulates Insulin-Like Growth Factor-I (IGF-I) Receptor Expression and IGF-I-Induced Tyrosine Phosphorylation in an Osteosarcoma Cell Line: Interaction between p53 and Sp1

The insulin-like growth factor-I receptor (IGF-IR) is involved in tumorigenesis. The aim of the present study was to investigate whether the IGF-IR is a physiological target for p53 in osteosarcoma cells. The p53-induced regulation of IGF-IR levels was studied in a tetracycline-regulated expression system. When expressed in Saos-2, osteosarcoma cells that lack p53, wild-type p53 decreased, whereas mutated p53 increased IGF-IR expression, and IGF-I-induced tyrosine phosphorylation of the IGF-IR. Similarly, wild-type p53 decreased IGF-I-induced tyrosine phosphorylation of IRS-1. A functional and physical interaction between p53 and Sp1, in the regulation of the IGF-R, was studied in osteosarcoma cells. Expression of p53 decreased IGF-IR promoter activity, whereas no effect on promoter activity was seen by Sp1 expressed alone. However, Sp1 counteracted the inhibitory effect of p53 on IGF-IR promoter activity in a dose-dependent manner. Furthermore, wild-type and mutated p53 were coimmunoprecipitated with Sp1, indicating a physical interaction between p53 and Sp1. In conclusion, p53 regulates IGF-IR expression, as reflected by a reduction in IGF-IR protein and a parallel reduction in IGF-I-induced tyrosine phosphorylation of the IGF-IR and IRS-1 in an osteosarcoma cell line. These data indicate that the IGF-I receptor is a physiological target for p53 in osteosarcoma cells. Furthermore, data supporting an interaction between p53 and Sp1 in the regulation of the promoter activity of IGF-IR are presented.

[1]  H. Findley,et al.  Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. , 1997, Blood.

[2]  A. Sacchi,et al.  The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal , 1997, Molecular and cellular biology.

[3]  M. Rubini,et al.  The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. , 1997, Experimental cell research.

[4]  D. Leroith,et al.  Insulin-like Growth Factor 1 Inhibits Apoptosis Using the Phosphatidylinositol 3′-Kinase and Mitogen-activated Protein Kinase Pathways* , 1997, The Journal of Biological Chemistry.

[5]  D. Leroith,et al.  Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. , 1997, Endocrinology.

[6]  A. Levine,et al.  Wild-type p53 negatively regulates the expression of a microtubule-associated protein. , 1996, Genes & development.

[7]  A. Ferber,et al.  A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. , 1996, Cancer research.

[8]  H. Werner,et al.  Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  N. Webster,et al.  Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. , 1996, Cancer research.

[10]  F. Kashanchi,et al.  Regulation of insulin-like growth factor II P3 promotor by p53: a potential mechanism for tumorigenesis. , 1996, Cancer research.

[11]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[12]  H. Werner,et al.  The Role of the Insulin‐like Growth Factor‐I Receptor in Cancer , 1995, Annals of the New York Academy of Sciences.

[13]  H. Werner,et al.  Regulation of insulin-like growth factor I receptor gene expression by Sp1: physical and functional interactions of Sp1 at GC boxes and at a CT element. , 1995, Molecular endocrinology.

[14]  R. Baserga,et al.  Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. , 1995, Cancer research.

[15]  A. Baldwin,et al.  p53 and Sp1 Interact and Cooperate in the Tumor Necrosis Factor-induced Transcriptional Activation of the HIV-1 Long Terminal Repeat (*) , 1995, The Journal of Biological Chemistry.

[16]  H. Werner,et al.  Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression , 1995, Molecular and cellular biology.

[17]  J. Kajstura,et al.  The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. , 1995, Cancer research.

[18]  C T Roberts,et al.  Molecular and cellular aspects of the insulin-like growth factor I receptor. , 1995, Endocrine reviews.

[19]  R. Baserga,et al.  The insulin-like growth factor I receptor: a key to tumor growth? , 1995, Cancer research.

[20]  R. Baserga.  Oncogenes and the strategy of growth factors , 1994, Cell.

[21]  L. Buckbinder,et al.  Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  B. Vogelstein,et al.  Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  V. Sukhatme,et al.  Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. , 1994, The Journal of biological chemistry.

[24]  M. Rubini,et al.  Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Hollstein,et al.  Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.

[26]  V. Sukhatme,et al.  Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Pipas,et al.  Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53 , 1993, Nature.

[28]  R. Glazer,et al.  Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. , 1993, The Journal of biological chemistry.

[29]  S. N. Agoff,et al.  Regulation of the human hsp70 promoter by p53. , 1993, Science.

[30]  H. Werner,et al.  Structural and functional analysis of the insulin-like growth factor I receptor gene promoter. , 1992, Molecular endocrinology.

[31]  A. Levine,et al.  Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. , 1992, Genes & development.

[32]  M. Botchan,et al.  The retinoblastoma gene product regulates Sp1-mediated transcription , 1992, Molecular and cellular biology.

[33]  K. Kinzler,et al.  Oncogenic forms of p53 inhibit p53-regulated gene expression. , 1992, Science.

[34]  I. Goldfine,et al.  Cloning and characterization of the human insulin-like growth factor-I receptor gene 5'-flanking region. , 1992, DNA and cell biology.

[35]  R. Tjian,et al.  Different activation domains of Sp1 govern formation of multimers and mediate transcriptional synergism. , 1991, Genes & development.

[36]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[37]  D. Cooke,et al.  Analysis of the human type I insulin-like growth factor receptor promoter region. , 1991, Biochemical and biophysical research communications.

[38]  N. Andrews,et al.  A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. , 1991, Nucleic acids research.

[39]  J. McCubrey,et al.  Growth-promoting effects of insulin-like growth factor-1 (IGF-1) on hematopoietic cells: overexpression of introduced IGF-1 receptor abrogates interleukin-3 dependency of murine factor-dependent cells by a ligand-dependent mechanism. , 1991, Blood.

[40]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[41]  H. Werner,et al.  Cloning and characterization of the proximal promoter region of the rat insulin-like growth factor I (IGF-I) receptor gene. , 1990, Biochemical and biophysical research communications.

[42]  M. Oren,et al.  Oligomerization of oncoprotein p53 , 1988, Journal of virology.

[43]  J. Fogh,et al.  Absence of HeLa cell contamination in 169 cell lines derived from human tumors. , 1977, Journal of the National Cancer Institute.

[44]  G. Scatchard,et al.  THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .